Publications

A Phase Ii, Open-Label, Extension Study of Long-Term Patisiran Treatment in Patients with Hereditary Transthyretin-Mediated (Hattr) Amyloidosis

AuthID
P-00S-ESG

Author(s)

Coelho, T

Adams, D

Waddington Cruz, M

Buades, J

Polydefkis, M

Wang, JJ

Chen, JH

Sweetser, MT

Gollob, J

Suhr, OB

Document Type

Article

Year published

2020

Published

in ORPHANET JOURNAL OF RARE DISEASES, ISSN: 1750-1172

Volume: 15, Issue: 1

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1186/s13023-020-01399-4

Pubmed: 32641071

Scopus: 2-s2.0-85087693350

Wos: WOS:000551966000001

Source Identifiers

ISSN: 1750-1172

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

A Phase Ii, Open-Label, Extension Study of Long-Term Patisiran Treatment in Patients with Hereditary Transthyretin-Mediated (Hattr) Amyloidosis

Useful Links

Get Help

Federated Authentication (Click on the image)

A Phase Ii, Open-Label, Extension Study of Long-Term Patisiran Treatment in Patients with Hereditary Transthyretin-Mediated (Hattr) Amyloidosis

Useful Links

Get Help